Pelthos Therapeutics Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Pelthos Therapeutics Inc. (PTHS) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $6.54 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-13
- Pelthos Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $14.20M.
- Pelthos Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$382.00K, a 110.40% decline year-over-year.
- Pelthos Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $3.67M.
- Pelthos Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$6.47K.
- Pelthos Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $17.51M, a 4099.04% increase from fiscal 2024.
- Pelthos Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $417.00K, a 909.27% increase from fiscal 2023.
- Pelthos Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $41.32K, a 24.98% decline from fiscal 2022.
- Pelthos Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $55.07K.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $6.54M 10-Q · filed 2026-08-13 | |||||||
| 2026-03-31 | $14.20M 10-Q/A · filed 2026-08-13 | |||||||
| 2025-12-31 | $17.51M 10-K · filed 2026-03-19 | |||||||
| 2025-09-30 | $13.74M 10-Q · filed 2025-11-13 | |||||||
| 2025-06-30 | -$454.00K 10-Q · filed 2026-08-13 | -$454.27K 10-Q · filed 2025-08-13 | ||||||
| 2025-03-31 | -$382.00K 10-Q/A · filed 2026-08-13 | -$382.13K 10-Q · filed 2025-05-13 | ||||||
| 2024-12-31 | $417.00K 10-K · filed 2026-03-19 | $417.05K 10-K · filed 2025-03-27 | ||||||
| 2024-09-30 | $1.16M 10-Q · filed 2025-11-13 | $1.16M 10-Q · filed 2024-11-13 | ||||||
| 2024-06-30 | $2.31M 10-Q · filed 2025-08-13 | |||||||
| 2024-03-31 | $3.67M 10-Q · filed 2025-05-13 | |||||||
| 2023-12-31 | $41.32K 10-K · filed 2025-03-27 | |||||||
| 2023-09-30 | -$32.29K 10-Q · filed 2024-11-13 | |||||||
| 2023-06-30 | $26.82K 10-Q · filed 2024-08-13 | |||||||
| 2023-03-31 | -$6.47K 10-Q · filed 2024-05-15 | |||||||
| 2022-12-31 | $55.07K 10-K · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |